A61K 40/4214
Receptors for cytokines
Official title: {Receptors for cytokines}
A61K40/4214 (Receptors for cytokines) appears on 506 US grants and 1,297 published applications in this corpus.
Search patents in A61K- Granted patents
- 506
- Published applications
- 1,297
- Assignees
- 451
- Inventors
- 2,181
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 0 | 7 |
| 2004 | 2 | 6 |
| 2005 | 1 | 2 |
| 2006 | 0 | 5 |
| 2007 | 0 | 2 |
| 2008 | 0 | 3 |
| 2009 | 2 | 3 |
| 2010 | 1 | 4 |
| 2011 | 0 | 7 |
| 2012 | 3 | 3 |
| 2013 | 3 | 3 |
| 2014 | 2 | 5 |
| 2015 | 4 | 6 |
| 2016 | 5 | 17 |
| 2017 | 7 | 29 |
| 2018 | 9 | 48 |
| 2019 | 24 | 91 |
| 2020 | 53 | 138 |
| 2021 | 54 | 149 |
| 2022 | 60 | 146 |
| 2023 | 63 | 168 |
| 2024 | 67 | 170 |
| 2025 | 80 | 172 |
| 2026 | 64 | 113 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Compositions and methods for modifying a target nucleic acid6 Oct 2026US 12,753,412 B2The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
- Compositions and methods for selective protein degradation29 Sep 2026US 12,747,272 B2Novartis AG
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Chimeric Cytokine Receptors and Methods of Use8 Oct 2026US 2026/0308235 A1
- Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof1 Oct 2026US 2026/0297151 A1Medicenna Therapeutics Inc.
- Viral vectors for glioblastoma cell therapy24 Sep 2026US 2026/0284109 A1
- Methods and materials for treating cancer24 Sep 2026US 2026/0284192 A1Mayo Foundation for Medical Education and Research
Most cited
By later US patents
- Methods related to immunostimulatory nucleic acid-induced interferon110US 6,949,520 B1Coley Pharmaceutical GmbH · 2005
- Chimeric immunoreceptor useful in treating human gliomas101US 8,324,353 B2City of Hope · 2012
- Treatment of cancer using a CD123 chimeric antigen receptor95US 9,815,901 B2Novartis AG · 2017
- Treatment of cancer using a CD33 chimeric antigen receptor86US 9,777,061 B2Novartis AG · 2017
- Chimeric antigen receptors targeting B-cell maturation antigen85US 9,765,342 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2017